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Abstract  
Osteoarthritis (OA) is characterized by cartilage degradation, inflammation and hypertrophy. 
Therapies are mainly symptomatic and aim to manage pain. Consequently, medical 
community is waiting for new treatments able to reduce OA process. This study aims to 
develop an in vitro simple OA model useful to predict drug ability to reduce cartilage 
hypertrophy.  
Human primary OA chondrocytes were incubated with transforming growth factor beta 1 
(TGF-β1). Hypertrophy was evaluated by Runx2, type X collagen, MMP13 and VEGF 
expression. Cartilage anabolism was investigated by Sox9, aggrecan, type II collagen and 
glycosaminoglycan expression. 
In chondrocytes, TGF-β1 increased expression of hypertrophic genes and activated canonical 
WNT pathway, while it decreased dramatically cartilage anabolism, suggesting that this 
treatment could mimic some OA features in vitro. Additionally, EZH2 inhibition, that has 
been previously reported to decrease cartilage hypertrophy and reduce OA development in 
vivo, attenuated COL10A1 and MMP13 upregulation and SOX9 downregulation induced by 
TGF-β1 treatment. Similarly, pterosin B (an inhibitor of Sik3), and DMOG (a hypoxia-
inducible factor prolyl hydroxylase which mimicks hypoxia), repressed the expression of 
hypertrophy markers in TGF-β stimulated chondrocytes. 
In conclusion, we established an innovative OA model in vitro. This cheap and simple model 
will be useful to quickly screen new drugs with potential anti-arthritic effects, in 
complementary to current inflammatory models, and should permit to accelerate development 
of efficient treatments against OA able to reduce cartilage hypertrophy. 
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Introduction 
Osteoarthritis (OA) is the most common rheumatologic disease worldwide, affecting more 
than 151 million of persons worlwide (1). Disability and pain resulting from OA usually 
affects life quality of patients. Furthermore, it is highly onerous, costing up to 2.5% of gross 
domestic product in the western world (2).  
OA is characterized by loss of articular cartilage, osteophyte formation, subchondral bone 
changes, fibrosis, and in many patients by inflammation. This disease is challenging to 
manage because of the absence of cartilage self-repair. Currently, treatments are symptomatic 
and mainly aim to reduce pain and inflammatory eruptions. At advance stages, surgical 
procedures are inevitable, and prosthesis are employed to replace damaged joints. However, 
in about twenty percent of the patients, this procedure does not result in a pain free joint (3). 
Consequently, medical community is waiting for treatments able to reduce OA process. 
However, the development of new anti-arthritic drugs is challenging in particular due to the 
absence of in vitro model able to mimic all OA hallmarks.  
Chondrocytes in OA cartilage show an aberrant phenotype and actively produce cartilage-
degrading enzymes, such metallopeptidases (MMPs) and aggrecanases. Age and activation of 
inflammatory cytokines play a role in these changes. Additionally, during OA, articular 
chondrocytes taking a differentiation route resembling that of growth plate chondrocytes, 
expressing hypertrophy-like changes. They express type X collagen and MMP-13. These 
phenotype changes having similarities to terminal differentiating chondrocytes, are 
accompanied by acquisition of an autolytic phenotype resulting in destruction of the 
surrounding cartilage (4).  
Human articular chondrocytes (HAC) treatment with interleukin-1 (IL-1)-β is the most 
approved in vitro OA model (5–7). Its advantage is to mimic the process of inflammation, but 
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it does not take into account the other components of the disease, especially cartilage 
hypertrophy.  
Clinical studies have shown that TGF-β levels are very low or absent in normal articular 
joints, while they are elevated in OA patients synovium and cartilage (8–13). These elevated 
levels of TGF-β in OA joints activate cells that are not normally exposed to high levels of 
TGF-β, leading to an altered cellular differentiation which may contribute to OA pathogenesis 
(3). Experimental OA models in mice confirm the involvement of TGF-β, and particularly 
TGF-β1, in development of this disabling disease. For instance, bolus injections of TGF-β1 or 
adenoviral overexpression of TGF-β1 in mouse knee joints induce the formation of 
osteophytes with structure and localization which are similar to osteophytes found in 
spontaneous murine OA (14,15). Additionally, the inhibition of TGF-β signaling pathways 
significantly decreases osteophyte formation in OA mice (16,17). These results indicate, that 
at least in experimental models, TGF-β is the main driver of osteophyte formation and 
chondrocyte hypertrophy (3). Beside its effect on osteophyte formation, TGF-β is also 
involved in inflammation. Intra-articular injection of rat knee joints with TGF-β results in 
swelling and erythema within one day (18). This TGF-β-induced inflammation contribute to 
joint damage in OA. These clinical and preclinical data conduct us to hypothesis that TGF-β1 
may be used in vitro to mimic some aspects of OA process.  
In this study, we investigated the effect of TGF-β1 in human OA articular chondrocytes, and 
evaluated the ability of three drugs known to reduce cartilage hypertrophy in vivo to 
counteract TGF-β effects in vitro. Together, our data permit to validate that human OA 
articular chondrocytes treated with TGF-β1 could be used as an in vitro OA model to easily 
screen the ability of drugs to slow down disease progression and to reduce cartilage 
hypertrophy. 
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Materials and Methods 
Cell culture and treatments 
Human OA cartilage was obtained from the femoral heads of 20 patients undergoing hip 
replacement surgery (ages 49–85 years; median 73.5 years). The experimental protocol was 
approved by local ethical committee, named “Comité de Protection des Personnes Nord Ouest 
III” (agreement #A13-D46-VOL.19). All methods were performed in accordance with the 
relevant guidelines and regulations. Informed consent was obtained from all participants. 
They all signed agreement forms before the surgery, rendering to local legislation.  
Chondrocytes obtained as previously described (19). Briefly, cells were released by cartilage 
digestion with type XIV pronase (2 mg/ml for 30 minutes; Sigma-Aldrich) and type II 
collagenase (2 mg/ml for 15 hours; Thermofisher). The cells were then washed with PBS and 
seeded at 4 x 104 cells/cm2 in Dulbecco’s modified Eagle’s medium (DMEM), supplemented 
with 10% fetal bovine serum (FBS), 100 IU/ml of penicillin, 100 µg/ml of erythromycin and 
then incubated at 37°C in a humidified atmosphere containing 5% CO2 until they reached 
80% confluency. At this stage (about one week), cells were treated with TGF-β1 (R&D 
Biosystems; 5 ng/ml) for 1 or 2 days in the presence or absence of EPZ-6438 (Selleckchem), 
an EZH2 inhibitor also called tazemetostat, PterosinB (AOBIOUS), a Sik-3 inhibitor, and 
DMOG (Echelon Biosciences Inc), a drug mimicking hypoxia. 
 
Metalloproteinase 13 (MMP13) release assay 
MMP13 release into conditioned media was quantified using commercially available enzyme 
immunoassay kit (R&D Biosystems). Absorbance was determined at 450 nm with a 
wavelength correction set at 540 nm (Multiskan GO spectrophotometer, Thermo Scientific, 
France).  
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GAG release assay 
GAG release into the medium was measured using a sulfated glycosaminoglycan assay kit 
(Blyscan™, Biocolor) according manufacturer’s instructions. 
 
RNA isolation and real-time reverse transcription-polymerase chain reaction (RT-PCR) 
RNA was extracted with NucleoSpin® RNA (Macherey-Nagel) according to manufacturer’s 
protocol, and reverse transcribed into cDNA as previously described (5). Amplification of the 
generated cDNA was performed by real-time PCR using Step One Plus Real Time PCR 
system (Applied Biosystems) with appropriate primers. The relative mRNA level was 
calculated with the 2−ΔΔCT method. RPL13a expression was used as reference. 
 
Protein extraction and western blotting 
Cells were lysed and western blotting performed as previously described (5). The following 
antibodies were used: type I, II, and X type collagen (ab34710, ab182563, ab34712) were 
purchased from Abcam, aggrecan (AB10031) from Millipore, Sox9 (LS-C368527) from 
LSBio and β-actin (sc-47778), β-catenin (sc-7963), goat anti-mouse IgG-HRP and goat anti-
rabbit IgG-HRP from Santa Cruz Biotechnology. 
 
Immunocytochemistry 
Cells were washed once with PBS and fixed in 4%  PFA during 10 min. Then, cells were 
washed three times with PBS and incubated overnight at 4°C with a solution composed by 
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PBS, 0.25% Triton, 1% BSA and 1/100e dilution of H3K27me3 antibody (C36B11, Cell 
signaling). Next, cells were washed and incubated with a solution composed by PBS, 0.25% 
triton, 1% BSA, 1/1000e Hoechst solution and 1/400e dilution of Alexa Fluor 594 Goat IgG 
Anti Rabbit IgG (111-585-003, Jackson). Fluorescence was evaluated using EVOS FL Auto 2 
Cell Imaging System (ThermoFisher Scientific). 
 
Statistical analysis 
Statistical significance was determined by Student’s t-test. P-values less than 0.05 were 
considered significant. 
 
 
Results 
TGF-β1 increased the expression of genes associated to cartilage hypertrophy in OA 
chondrocytes 
First, we tested whether TGF-β1 treatment is able to regulate the expression of genes 
associated to cartilage hypertrophy in human OA articular chondrocytes in vitro. We 
incubated cells with 5 ng/ml TGF-β1 for 24h and 48h, and next observed cell morphology and 
analyzed the expression of several genes known to be upregulated in hypertrophic OA 
cartilage. We investigated the expression of type X collagen  (COL10A1) and Matrix 
Metallopeptidase 13 (MMP-13), the two most widely used markers of hypertrophic 
chondrocytes, as well as the expression of type I collagen (COL1A1), Runt Related 
Transcription Factor 2 (RUNX2), and Vascular endothelial growth factor (VEGF), which 
have also been associated to hypertrophy chondrocytes (4).  
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Microscopically, we did not observe any major difference in term of morphology between 
untreated cells and TGF-β treated-cells. It seems however, that TGF-β increased cell number 
(figure 1A). Concerning gene expression, TGF-β treatment strongly increased the level of 
mRNA of hypertrophic genes (COL10A1, MMP13, COL1A1, RUNX2 and VEGF) (figure 
1B).  This effect was also observed at protein level, at least for type X collagen and MMP-13 
(figure 1B and C). 
 
TGF-β1 activated β-catenin/WNT pathway in OA chondrocytes 
To confirm that TGF-β1 treatment is able to induce hypertrophy in OA chondrocytes, we 
investigated Wnt pathways. Indeed, this signaling pathway is the major regulator of 
chondrocyte hypertrophy. Elevated canonical WNT signaling drives OA development by 
increasing RUNX2 activity thereby boosting hypertrophic differentiation of chondrocytes 
(4,20).  
To investigate canonical WNT signaling, we analyzed the expression of β-catenin, and 
secreted frizzled-related protein 1 precursor (SFRP1). We found that in OA chondrocytes, 
TGF-β1 increased protein level of β-catenin (figure 2A), and down-regulated the WNT 
antagonist SFRP1 (figure 2B). This is coherent with an activation of canonical WNT 
signaling. 
 
TGF-β1 decreased cartilage anabolism in OA chondrocytes 
Cartilage hypertrophy is known to be also associated to a loss of the differentiated phenotype 
of chondrocytes, which is correlated to a decreased expression of SRY-Box 9 (Sox9), a 
crucial factor for chondrocytes, and a reduced deposit of cartilage matrix composed of type II 
9 
 
collagen (COL2A1), aggrecan (ACAN) and glycoaminoglycans (GAG). So, we investigated 
the expression of this cartilage markers in OA chondrocytes treated with TGF-β1 for 24h and 
48h. In these experimental conditions, TGF-β1 reduced COL2A1, ACAN and SOX9 
expression at both mRNA and protein levels (figure 3A and B). Additionally, TGF-β1 
decreased GAG production (figure 3C). 
Together, these results showed that TGF-β1 treatment in OA chondrocytes is able to mimic in 
vitro some OA traits, and to induce phenotype resembling to hypertrophic OA chondrocytes, 
suggesting that this model could be used to test the effects of putative anti-arthritic drugs on 
chondrocyte hypertrophy. 
   
EZH2 inhibition counteracted the increase of H3K27 trimethylation induced by TGF-
β1, and reduced hypertrophy in vitro 
Recently, it has been shown that the inhibition of Enhancer of zeste homolog 2 (EZH2), an 
histone methyltransferase, ameliorates osteoarthritis development in mouse OA model, 
through the reduction of cartilage hypertrophy (21). Consequently, an EZH2 inhibitor should 
be a good tool to test the ability of our in vitro model to predict ability of drugs to reduce 
cartilage hypertrophy in vivo.  
Herein, we investigated whether EPZ6438 (also named tazemetostat) counteracts TGF-β1-
induced hypertrophy phenotype in cultures of human OA chondrocytes. First, we showed that 
EPZ6438 reduced, as expected, the trimethylation of H3K27 (H3K27me3) in chondrocytes, 
proving that the drug has efficiency inhibited the histone methylase EZH2 (figure 4). In 
addition, we observed that TGF-β1 increased the proportion of H3K27me3 positive cells. This 
effect was counteracted by the presence of EPZ6438. 
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Next, we investigated EPZ6438 effect on the expression of genes associated to hypertrophic 
or differentiated articular chondrocytes. In human OA chondrocytes treated with TGF-β1, 
EZH2 inhibitor reduced the expression of hypertrophic genes, namely MMP13 and type X 
collagen, while it increased Sox9, type II collagen and aggrecan expression (figure 5). 
 
Pterosin B and DMOG reduced the expression of MMP13 and type X collagen in TGF-β 
stimulated chondrocytes 
Next, we investigated the effect of two others drugs which are have been described as 
candidate therapeutic for osteoarthritis due to their ability to reduce hypertrophy (figure 6). 
First, we tested pterosin B, a Sik3 pathway inhibitor, which delay chondrocyte hypertrophy 
and mineralization (22). As expected, we observed that pterosin B reduces COL10A1 
expression in TGF−β stimulated chondrocytes. Next, we studied the effects of 
dimethyloxalylglycine (DMOG), a hypoxia-inducible factor (HIF) prolyl hydroxylase, which 
mimics hypoxia in stabilizing HIF factors and enhancing their nuclear localization. Hypoxia 
and DMOG are known to reduce the expression of markers associated 
with chondrocyte hypertrophy, in particular type X collagen and MMP13 (23,24). Herein, we 
showed that in our in vitro model, DMOG reduced the expression of these two markers of 
hypertrophy. Together, these experiments confirms that human OA articular chondrocytes 
treated with TGF-β1 can be used as an in vitro OA model to easily screen the ability of drugs 
to reduce cartilage hypertrophy. 
 
Discussion 
In this paper, we established a simple model of culture able to mimic some features of 
osteoarthritis process, and particularly the shift of articular chondrocytes toward a 
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hypertrophic phenotype. This in vitro model could be useful to predict the ability of drugs to 
reduce cartilage hypertrophy and thus to slow down OA disease in vivo.  
Osteoarthritis is a complex disease, difficult to reproduce in vitro. At cartilage level, OA is 
characterized by a tissue erosion due mainly to inflammation, but also by the formation of 
osteophytes due to terminal differentiation of articular chondrocytes which become 
hypertrophic. Current in vitro models used to study molecular OA mechanisms or to test the 
anti-arthritic effects of drugs consist usually to mimic inflammation observed during OA, by 
treated chondrocytes with IL-1β or TNF-α. Indeed, these cytokines have been found at an 
elevated level in synovial fluid of OA patients. These models permit to evaluate the ability of 
drugs to reduce inflammation as well as to decrease the expression of enzymes involved in 
cartilage breakdown. However, they fail to reproduce the induction of hypertrophic phenotype 
of chondrocytes observed during OA pathology. Herein, we propose another model based on 
the incubation of OA chondrocytes with TGF-β1. This model could be very useful to screen 
new drugs against OA, in complement to inflammatory models (based on IL-1β or TNF-α), 
before performing preclinical trials in rodents.  
As IL-1β and TNF-α, TGF-β1 level has been found increased in joints of OA patients (3,4), 
and numerous studies show its involvement in OA process. Its role on cartilage is different in 
an OA joint than in a normal joint (3). It would be a protective effect in normal chondrocytes, 
whereas it would be harmful in aged and OA chondrocytes. Herein, in this study, we only 
used aged OA chondrocytes. It is possible that different results would be observed in young 
normal chondrocytes. In human OA chondrocytes, we observed that TGF-β1 treatment (5 
ng/ml) increased hypertrophic markers, notably MMP13 and type X collagen. Type X 
collagen is considered as the standard marker for chondrocyte hypertrophy. MMP13, as called 
collagenase-3, is one of the major enzymes involved in the degradation of OA cartilage. 
Although accepted as a hypertrophy marker, its synthesis can be induced in chondrocytes by 
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alternative routes, such as inflammation or mechanical stress (4). So, it can be also considered 
as a marker of inflammation and cartilage breakdown.  
Additionally, we showed that TGF-β1 activates the β-catenin/WNT pathway, and increases 
the expression of other hypertrophic markers, such as RUNX2 that is a master transcription 
factor involved in the control of chondrocyte hypertrophic differentiation, and that directly 
regulates the expression of type X collagen and MMP-13 (20,25–27).  
Contrary to hypertrophic genes, the markers of differentiated chondrocytes (SOX9, COL2A1, 
ACAN) were down-regulated by TGF-β1 treatment. This is coherent with observation of the 
reduced synthesis of cartilage during advanced stage of osteoarthritis. Consequently, 
treatment of human OA chondrocytes with TGF-β1 mimics numerous features observed 
during osteoarthritis. This culture method could thus be useful to reproduce chondrocyte 
hypertrophy in vitro, permitting to study molecular mechanisms involved in this process and 
to test putative new treatments against OA before animal experimentation.  
To confirm the efficiency of this culture model to predict drug ability to reduce cartilage 
hypertrophy during OA, we investigated the effect of three drugs known for the ability to 
reduce cartilage hypertrophy. First, we tested an epidrug on the expression of a panel of gene 
regulated by TGF-β1 in human OA chondrocytes. We found that EZH2 inhibition by EPZ-
6438 opposites to the major effects of TGF-β1: it increases COL2A1, ACAN as well as SOX9 
expression and decreases MMP13 and COL10A1 synthesis. These results are fully in 
agreement with published data from in vivo experiments showing that intra-articular injections 
of an inhibitor of histone methyltransferase enhancer of zeste homolog 2 (EZH2), a chromatin 
modifier that activates Wnt/β-catenin signaling, reduced cartilage hypertrophy and also 
decreased articular cartilage degradation in surgically induced osteoarthritis (21). We also 
validate our model using two others drugs, pterosin B (a Sik-3 inhibitor) and DMOG (a mimic 
of hypoxia), which are known to reduce hypertrophy cartilage in vivo (22,24). 
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In conclusion, we established a model able to induce chondrocyte hypertrophy in vitro, which 
permits to evaluate the ability of drugs to reduce cartilage hypertrophy. This tool should be 
useful to identify more quickly new drugs having anti-arthritic action. In addition, this study 
confirms that TGF-β1 induces harmful effects in OA chondrocytes, suggesting that 
therapeutic strategy aiming to favor TGF-β1 signaling to treat OA should be used with 
important precaution, and be very well controlled.  
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Figure legends 
Figure 1: TGF-β1 stimulates chondrocytes hypertrophy. 
Human primary OA chondrocytes were treated with TGF-β1 (5 ng/ml) for 24h or 48 h. After 
treatment, RNA and proteins were extracted. 
(A) Photography of cells after treatments. 
(B) Relative mRNA expression of hypertrophy genes (type I and X collagen, Runx2, VEGF 
and MMP-13) was determined by real-time RT-PCR. Values were expressed as relative gene 
expression compared to untreated cells. Histograms represent means ± SEM (n=5).  *: p-
value ≤ 0.05; **: p-value ≤ 0.01. 
(C) Protein expression of type I and X collagen was analyzed by Western-blot. Figure 
represents an image representative of results from 3 independent experiments. 
 (D) MMP-13 release in medium was determined by ELISA assay. Data are expressed as 
means ± SEM (n=3). *: p-value ≤ 0.05. 
 
Figure 2: TGF-β1 activates β-catenin/WNT pathway.  
Primary OA chondrocytes were treated with TGF-β1 (5 ng/ml) for 24h and 48h.  
(A) After treatment, mRNA was extracted, and SIRP1 mRNA expression was determined by 
real-time RT-PCR. Data are expressed as means ± SEM (n=5).  **: p-value ≤ 0.01.  
(B) Proteins were extracted and β-catenin expression was evaluated by western blot (n=3).  
 
Figure 3: TGF-β1 reduces the expression of genes involved in cartilage anabolism 
Primary OA chondrocytes were treated as previously.  
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(A) COL2A1, ACAN and Sox9 expression were determined at mRNA level by RT-PCR. 
Data are expressed relative to untreated cells. Histograms represent means ± SEM (n=5). **: 
p-value ≤ 0.01.  
(B) Protein expression were evaluated by western blot (n=3).  
(C) GAG release into the medium was measured by Blyscan assay. Data are expressed as 
means ± SEM (n=3). *: p-value ≤ 0.05; **: p-value ≤ 0.01.  
 
Figure 4: EZH2 inhibition counteracts the increase of H3K27 trimethylation induced by 
TGF-β1 
Primary chondrocytes were treated with TGF-β1 (5 ng/ml) in the presence or absence of EPZ-
6438 (10 µM) for 48 h.  
(A) After treatment, H3K27me3 levels (red) were evaluated by immunohistology. Nucleus 
was marked by Hoescht staining (blue)  
(B) H3K27me3 positive cells were quantified in three independent experiments. For each 
experiments, at least twenty cells were counted. Data are expressed as means ± SEM (n=3). *: 
p-value ≤ 0.05; **: p-value ≤ 0.01. 
 
Figure 5: EPZ6438 counteracts the effects of TGF-β1 in OA chondrocytes.  
Primary chondrocytes were treated with TGF-β1 (5 ng/ml) in the presence or absence of EPZ-
6438 (10 µM) for 48 h. After treatment, RNA and proteins were extracted.  
(A) mRNA relative expression of type X collagen, MMP-13, Sox9, COL2A1 and ACAN 
was determined by real-time RT-PCR. Data are expressed as means ± SEM relative to gene 
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expression in TGF-β1-treated cells (n=4). Histograms represents. *: p-value ≤ 0.05; **: p-
value ≤ 0.01.  
(B) Protein expression of collagen type X was determined by western blot (n=3).  
(C) MMP13 release in medium was determined by ELISA assay. Data are expressed as 
means ± SEM (n=3). *: p-value ≤ 0.05.  
 
Figure 6: Pterosin B and DMOG reduced the expression of MMP13 and type X collagen 
in TGF-β stimulated chondrocytes 
Primary chondrocytes were treated with TGF-β1 (5 ng/ml) in the presence or absence of 
PterosinB (300µM) or DMOG (500µM) for 48 h. After treatment, RNA were extracted. 
mRNA relative expression of type X collagen and MMP-13 was determined by real-time RT-
PCR. Data are expressed as means ± SEM relative to gene expression in TGF-β1-treated cells 
(n=3). Histograms represents. *: p-value ≤ 0.05; **: p-value ≤ 0.01.  
 
 
 






